Radionuclide

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Retrieved on: 
Thursday, February 22, 2024
Neoplasm, Actinium-225, Cancer, Radionuclide, Therapy, Receptor (biochemistry), Patient, Clinical trial, Pancreatic cancer, PET

This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.

Key Points: 
  • This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
  • Figure 1 below shows the before and after optimization of MNPR-101-Zr, Monopar’s radiopharmaceutical imaging agent for advanced solid tumors expressing uPAR.
  • Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes.
  • “We are aiming to present these promising preclinical results at an upcoming scientific meeting.”

EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Monday, February 5, 2024
Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.

Eckert & Ziegler to Supply Nucleus RadioPharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Wednesday, January 31, 2024
Research, Genetics, Health Technology, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply, and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.

US Nuclear Strategic Investment in Fusion Energy Breakthrough Targets $7.5 Billion Medical Radioisotope Market for First Use

Retrieved on: 
Monday, January 22, 2024
US Nuclear Corp, Radionuclide, Hydra, Cancer, Sale, Neutron, Flash, Therapy, Lithium

Radioisotopes are used in several industries, but most notably for advanced medical imaging and therapeutics to diagnose and treat cancer and heart disease.

Key Points: 
  • Radioisotopes are used in several industries, but most notably for advanced medical imaging and therapeutics to diagnose and treat cancer and heart disease.
  • While there is a global need for more radioisotope production, producing them requires large numbers of neutrons which are not easy to find.
  • With successful world record neutron production in the past year of testing, US Nuclear Corp is targeting the medical radioisotope market for the first use of this breakthrough technology.
  • Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov , or the company’s website at www.usnuclearcorp.com .

Zeno Power Secures Radioisotope Fuel Supply from DOE to Build Full-Scale RPSs

Retrieved on: 
Friday, January 26, 2024
Entrepreneurship, Space, DOE, Partnership, Environmental resource management, Oak Ridge National Laboratory, Recycling, NASA, OAK, Pacific Northwest National Laboratory, Orbit, RPS, Radionuclide, Moon, DOD

OAK RIDGE, Tenn., Jan. 26, 2024 /PRNewswire/ -- Zeno Power announced today that it has secured Strontium-90 (Sr-90) material from the U.S. Department of Energy (DOE) to fuel its initial full-scale radioisotope power systems (RPSs) for national security and space exploration missions.

Key Points: 
  • OAK RIDGE, Tenn., Jan. 26, 2024 /PRNewswire/ -- Zeno Power announced today that it has secured Strontium-90 (Sr-90) material from the U.S. Department of Energy (DOE) to fuel its initial full-scale radioisotope power systems (RPSs) for national security and space exploration missions.
  • RPSs are compact devices that convert heat from the decay of radioisotopes into a persistent and reliable supply of clean energy.
  • Space, the Arctic, and the seabed are increasingly strategic domains in the wake of renewed great power competition.
  • Through a new public-private partnership, Zeno Power and DOE's Oak Ridge Office of Environmental Management (OREM) will recycle a legacy Sr-90 RPS – the BUP-500 – into fuel for Zeno's RPSs.

ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board

Retrieved on: 
Tuesday, January 16, 2024
Engineering, Patient, Head, Industrial organization, Institute of technology, CFO, Knowledge, CBO, Science, NOVA, Good manufacturing practice, Cancer, GMP, Good, Mechanical, Quality of life, Supervisory board, ITM, CNL, Actinium-225, Therapy, Doctor of Philosophy, Research and development, Research, Pleasure, Societas Europaea, Radionuclide, ITM Group of Institutions, Mechanical engineering, Growth, Management

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.

Key Points: 
  • Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board.
  • Since 2016, he has held the position of Chief Operating Officer (COO) and Managing Director of ITM Medical Isotopes GmbH, a subsidiary of ITM SE.
  • As a Societas Europaea (“SE”) entity, ITM SE is governed by a two-tier board structure consisting of an Executive Board and a Supervisory Board, in which the latter oversees the Executive Board.
  • Under this framework, the Executive Board is comprised of members of the management team, while the Supervisory Board is generally controlled by shareholders.

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Retrieved on: 
Tuesday, January 9, 2024
Glomus tumor, Patient, Therapy, Isotope, Cancer, CATX, Sale, GRPR, IND, Acquisition, LNTH, Toxicity, PSMA, Radionuclide, File, Medical imaging

Perspective Therapeutics agrees to acquire radiopharmaceutical manufacturing facility in Somerset, New Jersey

Key Points: 
  • Perspective Therapeutics agrees to acquire radiopharmaceutical manufacturing facility in Somerset, New Jersey
    SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced it entered into strategic agreements with Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company, and its affiliates (Lantheus) (NASDAQ: LNTH).
  • Additionally, Perspective has agreed to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price.
  • Thijs Spoor, Chief Executive Officer of Perspective, stated, "At Perspective Therapeutics, our goal is to leverage the best isotopes and provide effective therapeutic choices for patients with difficult-to-treat cancers.
  • The closing of Perspective’s acquisition of the Somerset facility and related assets is subject to customary closing conditions, including regulatory approval.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

Retrieved on: 
Thursday, January 4, 2024
Radionuclide, Quality control, Waste management, Cancer, Laboratory, RPT, NOVA, ITM, Patient, Safety, Radiopharmaceutical, Automation, Medical imaging

Lutetium-177

Key Points: 
  • Lutetium-177
    Garching / Munich, January 4, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the receipt of the Radioactive Material Handling License (RAM License) for the company’s NOVA facility , the world’s largest Lutetium-177 production site.
  • Having obtained the RAM License together with other regulatory approvals required, ITM has achieved operational readiness.
  • The fit-out of NOVA has been completed, with all major production, safety and quality control systems installed.
  • Based on its size and production scale, NOVA could potentially serve up to several hundred thousand patients worldwide per year.

ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 21, 2023
Radionuclide, Cancer, PST, Quality of life, Conference, Patient, Therapy, CFO, ITM

Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
  • Steffen Schuster will present a corporate overview on Tuesday, January 9, 2024, at 9:00 am PST.
  • ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.
  • We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply.